《股市简讯》中国生物制药涨2.3%，联合开发的药物纳入突破性治疗程序

路透中文

2025/06/27

《股市简讯》<a href="https://laohu8.com/S/01177">中国生物制药</a>涨2.3%，联合开发的药物纳入突破性治疗程序

* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周五早盘涨幅扩大至2.3%。

* 该公司此前公告称，联合开发的LM-108已被中国国家药品监督管理局药品审评中心纳入突破性治疗药物程序，用于联合特瑞普利单抗治疗既往接受一线标准治疗失败的CCR8阳性晚期胃╱胃食管结合部腺癌。

* 中国生物制药今年迄今劲涨64.4%，同期恒生指数.HSI大幅上扬21.8%。

* 恒生香港上市生物科技指数.HSHKBIO盘中一度跌1.7%。（完）

更多股市简讯请点选CN-CMN-HOT

(发稿徐凯文；审校吴云凌)

((kaiwen.xu@thomsonreuters.com))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2546760764"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546760764\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2546760764?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-06-27 11:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546760764","market":"us","top_or_hot":-1,"title":"《股市简讯》中国生物制药涨2.3%，联合开发的药物纳入突破性治疗程序","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>涨2.3%，联合开发的药物纳入突破性治疗程序</title></head><body><p>* 泰国富豪谢氏家族旗下制药公司--中国生物制药<span>1177.HK</span>周五早盘涨幅扩大至2.3%。</p><p>* 该公司此前公告称，联合开发的LM-108已被中国国家药品监督管理局药品审评中心纳入突破性治疗药物程序，用于联合特瑞普利单抗治疗既往接受一线标准治疗失败的CCR8阳性晚期胃╱胃食管结合部腺癌。</p><p>* 中国生物制药今年迄今劲涨64.4%，同期恒生指数<span>.HSI</span>大幅上扬21.8%。</p><p>* 恒生香港上市生物科技指数<span>.HSHKBIO</span>盘中一度跌1.7%。（完）</p><p>更多股市简讯请点选<span>CN-CMN-HOT</span></p><p> (发稿 徐凯文；审校 吴云凌)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>《股市简讯》中国生物制药涨2.3%，联合开发的药物纳入突破性治疗程序</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n《股市简讯》中国生物制药涨2.3%，联合开发的药物纳入突破性治疗程序\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-06-27 11:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>《股市简讯》<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>涨2.3%，联合开发的药物纳入突破性治疗程序</title></head><body><p>* 泰国富豪谢氏家族旗下制药公司--中国生物制药<span>1177.HK</span>周五早盘涨幅扩大至2.3%。</p><p>* 该公司此前公告称，联合开发的LM-108已被中国国家药品监督管理局药品审评中心纳入突破性治疗药物程序，用于联合特瑞普利单抗治疗既往接受一线标准治疗失败的CCR8阳性晚期胃╱胃食管结合部腺癌。</p><p>* 中国生物制药今年迄今劲涨64.4%，同期恒生指数<span>.HSI</span>大幅上扬21.8%。</p><p>* 恒生香港上市生物科技指数<span>.HSHKBIO</span>盘中一度跌1.7%。（完）</p><p>更多股市简讯请点选<span>CN-CMN-HOT</span></p><p> (发稿 徐凯文；审校 吴云凌)</p><p> ((kaiwen.xu@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ08YR35.GBP","symbol_name":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nL4T3SU07G:1","article_id":"2546760764","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546760764","pubTimestamp":1750993444,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"《股市简讯》中国生物制药涨2.3%，联合开发的药物纳入突破性治疗程序* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周五早盘涨幅扩大至2.3%。* 该公司此前公告称，联合开发的LM-108已被中国国家药品监督管理局药品审评中心纳入突破性治疗药物程序，用于联合特瑞普利单抗治疗既往接受一线标准治疗失败的CCR8阳性晚期胃╱胃食管结合部腺癌。* 中国生物制药今年迄今劲涨64.4%，同期恒生指数.HSI大幅上扬21.8%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","BK1191":"制药","BK1521":"挪威政府全球养老基金持仓","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","01177":"中国生物制药","BK1589":"北水核心资产","BK1515":"抗疫概念"},"translate_title":"\"Stock Market Newsletter\" China Biopharmaceuticals rose 2.3%, jointly developed drugs included in breakthrough therapeutic programs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"《股市简讯》中国生物制药涨2.3%，联合开发的药物纳入突破性治疗程序* 泰国富豪谢氏家族旗下制药公司--中国生物制药1177.HK周五早盘涨幅扩大至2.3%。* 该公司此前公告称，联合开发的LM-108已被中国国家药品监督管理局药品审评中心纳入突破性治疗药物程序，用于联合特瑞普利单抗治疗既往接受一线标准治疗失败的CCR8阳性晚期胃╱胃食管结合部腺癌。* 中国生物制药今年迄今劲涨64.4%，同期恒生指数.HSI大幅上扬21.8%。* 恒生香港上市生物科技指数.HSHKBIO盘中一度跌1.7%。（完）更多股市简讯请点选CN-CMN-HOT (发稿 徐凯文；审校 吴云凌) ((kaiwen.xu@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}